Groups Urge Fed. Circ. To Rethink Novo Nordisk Win
Amicus briefs calling for review of the U.S. Court of Appeals for the Federal Circuit's ruling for Novo Nordisk A/S in a fight over its diabetes drug Prandin are continuing to...To view the full article, register now.
Already a subscriber? Click here to view full article